Skip to content
Menu

Sibel Blau, MD

Board-Certified Oncologist & Hematologist in Puyallup, WA

Sibel Blau, MD.

Leave a Google Review

Specializing In

  • Breast Cancer
  • Hematology
  • Oncology
  • Stem Cell Transplantation

“Taking care of my patients has always been my passion and priority. I love my family and put myself in my patients’ and their family members’ place and become a member of their family as well. Feeling close to them helps me to guide their treatment by using the newest information and technology in a much more humane way in this very difficult and challenging road.” Sibel Blau M.D.

Dr. Sibel Blau is a Hematologist and Oncologist with special interest and expertise in breast cancer, multiple myeloma, and cell therapy.

She is the President/Executive Chair of the board at Northwest Medical Specialties, PLLC, where she also runs the clinical research and Precision Medicine program.

She is one of the founding members and the President/CEO and Co-Chair of ONCare Alliance, LLC that is a national organization with a focus of value-based care, education, and research, as well as Exigent Research, an innovative research network of independent practices throughout the US to provide high quality, accelerated and accessible research to the communities where patients are treated.  Quality Cancer Care Alliance Network (QCCA) and National Cancer Care Alliance (NCCA) merged to form ONCare Alliance. She is a board member and the current President of Washington State Medical Oncology Society (WSMOS). She is involved in multiple committees at national organizations like ASCO, COA, ACCC.

She is also a member of All4cure, which provides a transparent platform for oncologists with comprehensive displays of their patients’ data, cutting-edge analytic tools, and a real-time learning environment to empower the delivery of expert level myeloma care via clinical pathways that open a door to cooperative learning and new paradigms for curing myeloma.

To learn more and register to participate: www.all4cure.com/

She is the founder and president of the Journey Fund which is a community-based, not-for-profit organization committed to cancer patients facing barriers that affect their treatment with donations and community resources that make it possible for us to assist cancer patients facing social, financial, or emotional obstacles, toward a courageous journey, with dignity.

To learn more: https://journeyfund.org/

 

Languages Spoken: English, Turkish

Medical School: Cerrahpasa Medical School, Istanbul University, Istanbul, 1987

Residency: Internal Medicine, MHMC, CWRU, Cleveland, Ohio

Fellowship: Hematology-Oncology Fellowship, Case Western Reserve University, Cleveland, OH. Stem Cell Transplant Fellowship, Fred Hutchinson Cancer Research Center, Seattle, WA

Internship: Internal Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio

Board Certifications: Medical Oncology. Board Eligible for Internal Medicine, Hematology

Peer-Reviewed Publications:

  1. Dranitsaris G, Peevyhouse A, Neuhalfen H, et al., Blau S. A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. J Med Econ. 27 Dec 2025; 29(1): 30-40. DOI: 10.1080/13696998.2025.2604971
  2. Dranitsaris G, Neuhalfen H, Seifter N, et al., Blau S. Disparities in biopsy practice in metastatic breast cancer patients managed in community oncology practices in the United States: Implications for guideline-concordant care. Am. J. Clin. Oncol. 4 Dec 2025. DOI: 10.1097/COC.0000000000001281.
  3. Ermann DA, Dranitsaris G, Blau S, et al. A real-world comparative analysis of hypertension and time to treatment failure with Acalabrutinib vs. Ibrutinib in treatment-naive patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Blood. 5 Nov 2025; 144(1): 6367. DOI: 10.1182/blood-2024-210396
  4. Fasching PA, Bermejo B, Arkania E, et al., Blau S, et al. 293MO TACTIVE-N: phase 2 study of neoadjuvant vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer (BC). Ann Oncol. Sept 2025; 36(2): S322-S323. DOI: 10.1016/j.annonc.2025.08.722
  5. Fonseca R, Blau S, Varga C, et al. EMMpower: A longitudinal multi-center chart review consortium for multiple myeloma [Poster Presentation]. Presented at the 22nd International Myeloma Society Annual Meeting; 17-20 Sept 2025; Toronto, Canada. https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/emmpower-a-longitudinal-multi-center-chart-review-consortium-for-multiple-myeloma.pdf
  6. Khouri J, Fonseca R, Varga C, Blau S, et al. Real-world characteristics and outcomes of patients with relapsed or refractory multiple myeloma treated with talquetamab: Early results from eMMpower consortium [Poster Presentation]. Presented at the 22nd Annual International Myeloma Society (IMS); 17-20 Sept 2025; Toronto, Canada. https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/realworld-characteristics-and-outcomes-of-patients-with-relapsed-or-refractory-multiple-myeloma-trea.pdf
  7. Varga C, Khouri J, Oveisi D, Blau S, et al. Real-world safety outcomes and healthcare resource utilization (HCRU) during outpatient, inpatient, and hybrid step-up dosing (SUD) of teclistamab (Tec) and talquetamab (Tal): A chart review study [Poster Presentation]. Presented at the 22nd Annual International Myeloma Society (IMS); 17-20 Sept 2025; Toronto, Canada. https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/realworld-safety-outcomes-and-healthcare-resource-utilization-hcru-during-outpatient-inpatient-and-h.pdf
  8. Ermann D, Dranitsaris G, Blau S, et al. EE457 real-world study evaluating drug tolerability and health care resource use (HCRU) with acalabrutinib vs. Ibrutinib in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). V Health. July 2025; 28(6): S146. DOI: 10.1016/j.val.2025.04.2054
  9. Ermann D, Dranitsaris G, Blau S, et al. EE35 real-world study evaluating drug tolerability and health care resource use (HCRU) with acalabrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Value in Health. July 2025; 28(6): S67. DOI: 10.1016/j.val.2025.04.327
  10. Ermann DA, Dranitsaris G, Blau S, et al. A real-world comparative study of hypertension (HTN) and time to treatment failure (TTF) with acalabrutinib versus ibrutinib in treatment-naive Medicare-eligible patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol. 28 May 2025; 43(16): e23279. DOI: 10.1200/JCO.2025.43.16_suppl.e23279
  11. Kolodziej MA, Ascha M, Blau S, et al. Electronic patient reported outcomes in breast cancer patients receiving adjuvant chemotherapy with doxorubicin/cyclophosphamide combined with paclitaxel compared to patients receiving docetaxel/cyclophosphamide. J Clin Oncol. 28 May 2025; 43(16): e12519. DOI: 10.1200/JCO.2025.43.16_suppl.e12519
  12. Ermann DA, Dranitsaris G, Blau S, et al. A real-world comparative analysis of cardiovascular (CV) safety and time to next treatment (TTNT) with acalabrutinib versus ibrutinib in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol. 28 May 2025; 43(16): e23280. DOI: 10.1200/JCO.2025.43.16_suppl.e23280
  13. Mallahan S, Gajra A, Blau S, et al. Optimizing clinical trial subject selection: Insights from Exigent Research Network and the Tempus AI TIME Program Collaboration. AI in PO. 6 Dec 2024; 1(6). DOI: 10.1089/aipo.2024.0030
  14. Chhun L, Assonov D, Wren J, et al., Blau S, et al. Study assessing the All4Cure health technology intervention on patient activation in multiple myeloma. Blood. 5 Nov 2024; 144(1): 5043. DOI: 10.1182/blood-2024-194268
  15. Gajra A, Mallahan S, Blau S, et al. Impact of Exigent Research Network’s partnership with the Tempus AI TIME Program on the screening and matching of patients for clinical trials. J Clin Oncol. 29 May 2024; 42(16): e13599. DOI: 10.1200/JCO.2024.42.16_suppl.e13599
  16. Seneviratne LC, Harnden KK, Blau S, et al. Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results. J Clin Oncol. 29 May 2024; 42(16): 1091. DOI: 10.1200/JCO.2024.42.16_suppl.1091
  17. Bardia A, O’Sullivan CC, Mahtani RL, Blau S, et al. An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC). J Clin Oncol. 29 May 2024; 42(16): TPS1122. DOI: 101200/JCO.2024.42.16_suppl.TPS1122
  18. Kolodziej MA, Ascha MS, Frank A, et al., Blau S, et al. Symptoms reported by patients using an ePRO compared with those reported to nurses via telephone triage. J Clin Oncol. 29 May 2024; 42(16): 1542. DOI: 10.1200/JCO.2024.42.16_suppl.1542
  19. Ali K, Agrawal L, Thummala A, et al., Blau S, et al. Abstract PO1-04-02: ACE-Breast-03: A phase 2 study ARX788, a novel next-generation anti-HER antibody-drug conjugate in HER2-positive metastatic breast cancer patients previously treated with trastuzumab deruxtecan. Cancer Res. 2 May 2024; 84(9): PO1-04-02. DOI: 10.1158/1538-7445.SABCS23-PO1-04-02
  20. Damodaran S, O’Sullivan CC, Elkhanany A, et al., Blau S, et al. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE. Ann Oncol. Dec 2023; 34(12): 1131-1140. DOI: 10.1016/j.annonc.2023.09.3103
  21. Blau CA, Nam G, Chhun L, et al., Blau S, et al. Characteristics of a comprehensive, continuously updated longitudinal database for multiple myeloma. Blood. 23 Nov 2021; 138(1): 4969. DOI: 10.1182/blood-2021-148399
  22. Nagaraj G, Vinayak S, Raza Khaki A, et al., Blau S, et al. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) cohort study. Elife. 17 Oct 2023; 12: e82618. DOI: 10.7554/eLife.82618
  23. Schmid P, Cortes J, Joaquim A, et al., Blau S, et al. XENERA-1: A randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease. Breast Cancer Res. 12 Jun 2023; 25(1): 67. DOI: 10.1186/s13058-023-01649-w
  24. Moey MYY, Hennessy C, French B, et al., Blau S, et al. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease. Transl Oncol. 2 Jun 2023; 34: 101709. DOI: 10.1016/j.tranon.2023.101709
  25. Blau S, Antonio Peguero J, Moore HCF, et al. Operational metrics for the ELAINE 2 study combining a traditional approach with a just-in-TIME model. JCO Clin Cancer Inform. Jun 2023; 7: e2200164. DOI: 10.1200/CCI.22.00164
  26. Kolodziej MA, Kwiatkowsky L, Travis PM, Blau S, et al. Electronic patient-reported outcomes in a cohort of patients with lung cancer treated in the community with shorter versus longer course PD1/PDL1 therapy. J Clin Oncol. 31 May 2023; 41(16): e18810. DOI: 10.1200/JCO.2023.41.16_suppl.e18810
  27. Seneviratne L, Harnden K, Mardones M, Blau S, et al. Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (MTNBC): Preliminary phase 2 results [Poster Presentation]. Presented at ESMO Breast Cancer; 11-13 May 2023; Berlin, Germany. https://www.g1therapeutics.com/file.cfm/34/docs/esmo%20201p%20seneviratne%20final%20poster.pdf
  28. Seneviratne L, Harnden KK, Mardones M, Blau S, et al. 201P trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Preliminary phase II results. ESMO Open. May 2023; 8(1): 101390. DOI: 10.1016/j.esmoop.2023.101390
  29. Choueiri TK, Labaki C, Bakouny Z, et al., Blau S, et al. Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: A retrospective observational study from the COVID-19 and Cancer Consortium. Lancet Reg Health Am. 13 Feb 2023; 19: 100445. DOI: 10.1016/j.lana.2023.100445
  30. Sibel Blau, MD. Cardio-oncology: A component of comprehensive cancer care. Oncol Issues. 14 Nov 2022; 37(6): 2. DOI: 10.1080/10463356.2022.2135311
  31. Sibel Blau, MD. Reflections on the EOM. Oncol Issues. 26 Sept 2022; 37(5): 2. DOI: 10.1080/10463356.2022.2114773
  32. Sibel Blau, MD. Technology solutions in practice. Oncology Issues. 18 Jul 2022; 37(4): 2. DOI: 10.1080/10463356.2022.2090191
  33. Sibel Blau, MD. Access to cancer care – The perspective of an independent community oncologist. IJCCD. 23 June 2022; 1(1). DOI: 10.53876/001c.36152
  34. Blau S, Antonio Pegguero J, Moore HCF, et al. Operational metrics for the ELAINE II study combining a traditional approach with a just-in-time model. J Clin Oncol. 2 June 2022; 40(16): 1504. DOI: 10.1200/JCO.2022.40.16_suppl.1504
  35. Gajra A, Jeune-Smith Y, Balanean A, et al., Blau S. Impact of an augmented intelligence-based tool upon the timeliness of referrals to palliative care and hospice in patients with advanced cancer in the real-world setting. J Clin Oncol. 2 Jun 2022; 40(16): 12127. DOI: 10.1200/JCO.2022.40.16_suppl.12127
  36. Kolodziej MA, Kwiatkowsky L, Parrinello C, et al., Blau S. ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization. J Clin Oncol. 2 Jun 2022; 40(16): 1508. DOI: 10.1200/JCO.2022.40.16_suppl.1508
  37. Sibel Blau, MD. Independent oncology: An endangered species? Oncol Issues. 20 May 2022; 37(3): 2. DOI: 10.1080/10463356.2022.2065163
  38. Dranitsaris G, Moezi M, Dobson K, Phelan R, Blau S. A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer. 2 May 2022; 30(8): 6649-6658. DOI: 10.1007/s00520-022-07082-7
  39. Sibel Blau, MD. Critical mass. Oncol Issues. 25 Mar 2022; 37(2): 2. DOI: 10.1080/1043356.2022.2044152
  40. Burton KA, Mahen E, Quentin Konnick E, Blau S, et al. Safety, feasibility, and merits of longitudinal molecular testing of multiple metastatic sites to inform mTNBC patient treatment in the Intensive Trial of Omics in Cancer. JCO Precis Oncol. 16 Mar 2022; 6: e2100280. DOI: 10.1200/PO.21.00280
  41. Hurvitz SA, Clark AS, Rugo HS, et al., Blau S, et al. Abstract PD13-03: Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2- advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1. Cancer Res. 15 Feb 2022; 82(4): PD13-03. DOI: 10.1158/1538-7445.SABCS21-PD13-03
  42. Sibel Blau, MD. The OCM is ending, what’s next? Oncol Issues. 1 Feb 2022; 37(1): 2. DOI: 10.1080/10463356.2022.2015956
  43. Sibel Blau, MD. A focus on APPs. Oncol Issues. 19 Nov 2021; 36(6): 2. DOI: 10.1080/10463356.2021.1993135
  44. Sibel Blau, MD. A focus on our staff. Oncol Issues. 21 Sep 2021; 36(5): 2. DOI: 10.1080/10463356.2021.1967660
  45. Gajra A, Zettler ME, Miller KA, et al., Blau S. Impact of augmented intelligence on utilization of palliative care services in a real-world oncology setting. JCO Oncol Pract. 10 Sep 2021; 18(1): e80-e88. DOI: 10.1200/OP.21.00179
  46. Kline RM, Blau S, Buescher N, et al. Secret sauce – how diverse practices succeed in Centers for Medicare & Medicaid Services’ Oncology Care Model. JCO Oncol Pract. 18 Aug 2021; 17(12): 734-743. DOI: 10.1200/OP.21.00165
  47. Zon RT, Kennedy EB, Adelson K, Blau S, et al. Telehealth in oncology: ASCO standards and practice recommendations. JCO Oncol Pract. 28 Jul 2021; 17(9): 546-564. DOI: 10.1200/OP.21.00438
  48. Sibel Blau, MD. The masking conundrum. Oncol Issues. 19 Jul 2021; 36(4): 2. DOI: 10.1080/10463356.2021.1941654
  49. Dent R, Oliveira M, Isakoff SJ, et al., Blau S, et al. Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. Breast Cancer Res Treat. 15 Jul 2021; 189: 377-386. DOI: 10.1007/s10549-021-06143-5
  50. Gajra A, Zettler ME, Miller KA, Blau S, et al. Augmented intelligence to predict 30-day mortality in patients with cancer. Future Oncology. 30 Jun 2021; 17(29): 3797-3807. DOI: 10.2217/fon-2021-0302
  51. Sachse L, Dasari S, Ackermann M, et al., Blau S, et al. Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. J Clin Oncol. 28 May 2021; 39(15): e13588. DOI: 10.1200/JCO.2021.39.15_suppl.e13588
  52. Gajra A, Zettler ME, Ellis AR, et al., Blau S. Outcomes among patients with cancer previously identified as being at risk for 30-day mortality using augmented intelligence. J Clin Oncol. 28 May 2021; 39(15): 12031. DOI: 10.1200/JCO.2021.39.15_suppl.12031
  53. Bardia A, Hurvitz SA, DeMichele A, et al., Blau S, et al. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clin Cancer Res. 15 Mar 2021; 27(15): 4177-4185. DOI: 10.1158/1078-0432.CCR-20-2114
  54. Pennell NA, Dillmon M, Levit LA, et al., Blau S, et al. American Society of Clinical Oncology road to recovery report: Learning from the COVID-19 experience to improve clinical research and cancer care. J Clin Oncol. 8 Dec 2020; 39(2): 155-169. DOI: 10.1200/JCO.20.02953
  55. Khan QJ, O’Dea A, Bardia A, et al, Blau S, et al. Letrozole plus ribociclib compared to letrozole plus placebo as neoadjuvant therapy for ER positive early breast cancer (FELINE trial). ASCO Annual Meeting 2020 (Oral Presentation).

Locations

Facebook

Twitter

Instagram

YouTube